What are the common drug interactions with fostatinib?

Fostamatinib (Fostamatinib) is a kinase inhibitor commonly used to treat immune thrombocytopenia (ITP). Although fostatinib itself has an effective therapeutic effect, when used clinically, it may interact with other drugs, affecting its efficacy or causing side effects. Therefore, it is very important to understand these common drug interactions.

CYP3A4Inhibitors: Fostatinib is metabolized by the CYP3A4 enzyme in the liver. If used in combination with CYP3A4 inhibitors (such as fluconazole, erythromycin, itraconazole, etc.), the plasma concentration of fostatinib may increase. This interaction may increase the risk of adverse effects of fostatinib, such as hepatotoxicity, gastrointestinal symptoms, and hypertension. Therefore, patients should avoid concurrent use of strong CYP3A4 inhibitors when using fostatinib, or need to adjust the dose and monitor side effects according to the doctor's recommendations.

CYP3A4Inducers: On the contrary, CYP3A4 inducers (such as carbamazepine, phenobarbital, rifampicin) will increase the metabolism rate of fostatinib, resulting in a decrease in plasma concentration, thereby reducing its efficacy. Therefore, patients should avoid coadministration with these drugs or have the dose of fostatinib adjusted and monitor for efficacy if used concomitantly.

Immunosuppressive drugs: When fostatinib is used in combination with other immunosuppressive drugs (such as cyclosporine, methotrexate, etc.), the immunosuppressive effect may be enhanced. This may lead to an increased risk of infection, especially during long-term treatment. Therefore, when immunosuppressive drugs are used in combination, patients need to be closely monitored for signs of infection and their treatment regimen adjusted to reduce the risk of infection.

Anticoagulant drugs: When fostatinib is used together with anticoagulant drugs (such as warfarin, low molecular weight heparin, etc.), the risk of bleeding may be increased. The effects of fostatinib on platelets may be additive with anticoagulant drugs, leading to more severe bleeding events. Therefore, when using fostatinib, special attention needs to be paid to the combined use with anticoagulant drugs, and coagulation function should be checked regularly to avoid serious bleeding.

In summary, drug interactions with fostatinib need to be managed carefully, and patients should report all medications they are taking to their doctors when taking fostatinib to ensure safety and effectiveness.